Your browser is no longer supported. Please, upgrade your browser.
Autolus Therapeutics plc
Index- P/E- EPS (ttm)-2.75 Insider Own25.58% Shs Outstand52.21M Perf Week-7.73%
Market Cap370.80M Forward P/E- EPS next Y-1.85 Insider Trans0.00% Shs Float33.90M Perf Month-7.25%
Income-142.10M PEG- EPS next Q-0.60 Inst Own25.50% Short Float3.77% Perf Quarter-33.46%
Sales1.70M P/S218.12 EPS this Y4.20% Inst Trans42.35% Short Ratio1.38 Perf Half Y-55.03%
Book/sh4.02 P/B1.34 EPS next Y9.30% ROA-45.10% Target Price- Perf Year-49.91%
Cash/sh2.22 P/C2.42 EPS next 5Y- ROE-57.20% 52W Range4.94 - 17.19 Perf YTD-39.93%
Dividend- P/FCF- EPS past 5Y-53.50% ROI-68.60% 52W High-68.76% Beta-
Dividend %- Quick Ratio5.90 Sales past 5Y7.20% Gross Margin- 52W Low8.70% ATR0.39
Employees376 Current Ratio5.90 Sales Q/Q33.30% Oper. Margin- RSI (14)43.80 Volatility7.77% 6.98%
OptionableNo Debt/Eq0.00 EPS Q/Q10.50% Profit Margin- Rel Volume0.42 Prev Close5.10
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume927.50K Price5.37
Recom2.20 SMA20-2.89% SMA50-10.23% SMA200-45.94% Volume391,657 Change5.29%
Jan-29-21Downgrade JP Morgan Overweight → Neutral $9
Dec-28-20Resumed H.C. Wainwright Buy $19
Jul-31-20Initiated JP Morgan Overweight
Jul-22-20Initiated SunTrust Buy $38
Apr-22-20Initiated Mizuho Buy $18
Sep-23-19Initiated Needham Buy $26
May-17-19Reiterated H.C. Wainwright Buy $45 → $41
Oct-24-18Initiated H.C. Wainwright Buy $45
May-06-21 07:00AM  
Apr-26-21 07:00AM  
Apr-20-21 07:00AM  
Apr-19-21 07:00AM  
Apr-07-21 01:51AM  
Apr-01-21 04:01PM  
Mar-29-21 08:00AM  
Mar-04-21 07:00AM  
Mar-03-21 10:43AM  
Mar-02-21 04:18AM  
Feb-24-21 07:00AM  
Feb-12-21 04:01PM  
Feb-10-21 06:59AM  
Feb-09-21 08:42PM  
Feb-08-21 04:19PM  
Feb-05-21 12:57AM  
Feb-04-21 07:00AM  
Jan-27-21 12:00PM  
Jan-06-21 04:07AM  
Jan-04-21 07:00AM  
Dec-07-20 12:01PM  
Dec-05-20 03:01PM  
Dec-04-20 10:14AM  
Dec-01-20 08:55AM  
Nov-30-20 07:00AM  
Nov-17-20 07:00AM  
Nov-07-20 07:47AM  
Nov-06-20 05:30AM  
Nov-05-20 07:00AM  
Oct-30-20 07:00AM  
Sep-18-20 03:05AM  
Sep-08-20 07:00AM  
Sep-01-20 07:48AM  
Aug-06-20 07:00AM  
Aug-05-20 10:05AM  
Aug-04-20 07:00AM  
Jul-30-20 07:00AM  
Jul-02-20 04:39PM  
Jun-24-20 09:32AM  
Jun-22-20 07:00AM  
Jun-19-20 11:30AM  
Jun-12-20 02:30AM  
Jun-08-20 05:00PM  
Jun-03-20 06:28AM  
Jun-02-20 08:07AM  
May-29-20 07:37AM  
May-26-20 07:00AM  
May-22-20 07:00AM  
May-15-20 11:20AM  
May-14-20 07:00AM  
May-13-20 09:27AM  
May-12-20 12:00PM  
May-10-20 08:26AM  
May-09-20 11:01PM  
May-07-20 08:06AM  
May-01-20 07:00AM  
Apr-16-20 07:00AM  
Mar-03-20 07:07AM  
Feb-25-20 07:00AM  
Feb-24-20 07:00AM  
Jan-30-20 07:00AM  
Jan-27-20 04:00PM  
Jan-22-20 09:41PM  
Jan-13-20 07:00AM  
Jan-08-20 11:48AM  
Dec-20-19 06:30AM  
Dec-18-19 07:59AM  
Dec-14-19 07:47PM  
Dec-08-19 09:15AM  
Dec-07-19 02:00PM  
Dec-05-19 04:30PM  
Nov-27-19 07:03AM  
Nov-18-19 04:52AM  
Nov-13-19 04:02PM  
Nov-09-19 07:00AM  
Nov-07-19 07:06AM  
Nov-06-19 09:24AM  
Nov-05-19 09:35AM  
Oct-31-19 06:30AM  
Oct-30-19 07:01PM  
Oct-08-19 08:00AM  
Oct-03-19 09:08AM  
Sep-19-19 08:53AM  
Sep-16-19 10:34AM  
Sep-03-19 02:00AM  
Aug-28-19 04:05PM  
Aug-09-19 02:24AM  
Aug-08-19 07:49AM  
Aug-02-19 09:06AM  
Jul-16-19 10:31AM  
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.